Bristol-Myers Squibb and Incyte Corporation have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 inhibitor, INCB24360, in a Phase I/II study. Multiple tumor types will be explored in the study, which could potentially include melanoma, non-small cell lung, ovarian, colorectal , squamous cell carcinoma of the head and neck, and diffuse large B-cell lymphoma … more

 

Bristol-Myers Squibb and CytomX Therapeutics have signed a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody™ Platform. Probodies are monoclonal antibodies that are selectively activated within the cancer microenvironment, focusing the activity of therapeutic antibodies to tumors and sparing healthy tissue … more

— UPCOMING EVENTS —

6/5 4:00 pm – 6:00 pm in New Haven
CURE annual meeting and BioHaven panel discussion: “Growing Connecticut’s Bioscience Community: Supporting Ideas, Creating Value” … more

6/16 4:30 pm – 6:00 pm in Farmington
BioScienceClubhouseCT presents ‘CORNOVUS Pharmaceuticals: Novel Treatment for Heart Failure’ … more